Medical Marijuana Companies Sue DEA Over November 29 Deadline That Could Disrupt Cannabis Supply Chains

Medical Marijuana Companies Sue DEA Over November 29 Deadline

Seven medical marijuana companies operating in four states have launched federal legal challenges against the Drug Enforcement Administration (DEA), warning that new restrictions scheduled for November 29, 2026, could destabilize established cannabis supply chains, force businesses to close, and threaten patient access to medical marijuana. The lawsuits, filed November 18 and 19 in the U.S. Court of Appeals for the District of Columbia Circuit, challenge federal guidance requiring qualifying cannabis businesses to purchase and distribute products only through operators holding DEA registration or protected timely-applicant status. The companies argue that the agency has imposed sweeping commercial restrictions without providing sufficient time for state-regulated businesses to restructure their operations.

The dispute represents one of the first significant legal conflicts emerging from the federal government’s April 2026 decision to move qualifying medical marijuana activities into Schedule III of the Controlled Substances Act. Although the policy change was widely viewed as an important development for the cannabis industry, implementation has created uncertainty over federal registrations, manufacturing operations, and longstanding commercial relationships. Companies involved in the litigation predict hundreds of thousands of dollars in lost revenue, substantial employee layoffs, and possible insolvency. With the deadline approaching, the court must determine whether the DEA’s guidance should be temporarily suspended while the underlying legal challenges proceed.

DEA’s November 29 Deadline Creates New Restrictions on Cannabis Supply Chains

The controversy centers on guidance published October 30, 2026, titled “DEA Medical Marijuana Timely Applicant Information.” Under the agency’s interpretation of federal law, medical marijuana businesses that received federal registrations or submitted complete applications during the initial registration window may conduct covered Schedule III transactions only with other qualifying applicants or registered operators. Businesses that missed the application window cannot participate in those transactions with protected operators until they obtain federal registration. The policy effectively separates state-licensed medical cannabis businesses into different categories based on their federal application status, even when those companies have operated legally under state regulations for years.

The November 29 date is specifically a deadline for qualifying applicants to verify trading partners and establish compliant supply chains, not an opportunity for late applicants to receive additional temporary operating authority. The DEA expects operators to confirm registration status, obtain appropriate application documentation, verify active state licenses, and maintain records of their due diligence. Companies continuing prohibited transactions could face denial of pending federal applications or revocation of existing registrations. For businesses dependent on suppliers, processors, and dispensary customers that lack qualifying federal status, the requirements could force substantial changes to commercial relationships in less than a month.

Federal Marijuana Rescheduling Established a New Registration Framework

The legal conflict follows a major federal policy change announced by the Department of Justice in April 2026. Acting Attorney General Todd Blanche issued an order transferring FDA-approved marijuana products and cannabis regulated under qualifying state medical marijuana licenses from Schedule I to Schedule III. Effective April 28, the order established a new federal framework intended to incorporate existing medical marijuana programs while maintaining oversight under the Controlled Substances Act. Recreational marijuana remained outside the order’s protections, and a separate federal proceeding continued examining whether cannabis should receive broader Schedule III treatment.

To help existing medical marijuana businesses transition into the federal system, the government created an expedited registration process. Qualified state license holders that submitted complete applications between April 28 and June 26 could continue certain medical cannabis activities while the DEA reviewed their applications. On October 30, the Justice Department announced that more than 900 medical dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia had received federal registrations. Thousands of additional applications remained under review, including those submitted by manufacturers and distributors requiring more extensive inspections and compliance evaluations. The latest lawsuits challenge how the DEA is implementing that framework rather than seeking to reverse medical marijuana rescheduling itself.

Cannabis Businesses in Utah, Arizona and Oklahoma Warn of Financial Damage

The first legal challenge was filed November 18 by Standard Wellness Utah, Arizona-based Verde Americano, and NW Confections OK of Oklahoma. Their petition argues that the new restrictions fail to account for the realities of state cannabis markets, where companies typically depend on suppliers and customers operating within the same state. Because interstate marijuana commerce remains heavily restricted, businesses cannot simply replace disqualified local suppliers with companies operating elsewhere in the country. The petitioners contend that requiring federally protected businesses to abandon established trading relationships could damage both companies that applied on time and state-licensed operators that did not.

The companies describe significant potential financial consequences. Standard Wellness Utah estimates it could lose approximately $275,900 in average monthly sales, along with suppliers responsible for about 16% of its cannabis oil. The company also reports that one business partner quarantined approximately $80,000 worth of previously delivered product. Verde Americano warns that the disruption could require reducing its workforce by 70%, while NW Confections says the restrictions threaten the financial viability of its Oklahoma business. The Oklahoma processor identified 15 dispensary customers operating approximately 23 locations that would no longer qualify as trading partners under the DEA’s framework. These figures are allegations and projections submitted by the companies, not independently established losses resulting from an implemented deadline.

Pennsylvania Medical Marijuana Companies File a Second Lawsuit

A second group of businesses joined the legal fight on November 19, when four Pennsylvania medical marijuana companies filed their own petition challenging the DEA’s restrictions. The plaintiffs include G.P.M.II, LLC, MLH Explorations LLC, Tri-Mountain Pure, LLC, and Story of PA CR, LLC. The companies operate vertically integrated cannabis businesses combining cultivation, processing, and dispensary operations. G.P.M.II is associated with multistate operator INSA, while Story of PA CR is affiliated with Ascend Wellness Holdings. Their lawsuit raises a particularly complicated problem involving businesses that applied for federal protection for their dispensaries but did not obtain timely-applicant status for their manufacturing divisions.

According to the Pennsylvania petitioners, the DEA’s staggered introduction of registration procedures and inconsistent guidance created confusion over how different business activities needed to be registered. Their dispensaries submitted applications during the initial 60-day period, but their cultivation and manufacturing operations did not complete qualifying applications within that window. Under the October 30 guidance, the companies argue, their own dispensaries could be prevented from purchasing cannabis produced by their affiliated cultivation facilities. The businesses warn that they could be forced to purchase products from competitors, close manufacturing facilities, or lay off employees despite maintaining valid state licenses. The appeals court has consolidated the Pennsylvania case with the earlier challenge involving the Utah, Arizona, and Oklahoma operators.

Companies Argue the DEA Exceeded Its Legal Authority

The lawsuits advance several arguments challenging the DEA’s authority to impose its new restrictions. First, the petitioners maintain that the October guidance conflicts with the federal medical marijuana rescheduling order, which permitted qualifying applicants to operate under their state licenses while federal registration applications remained pending. They argue that the original framework did not expressly establish the November 29 supply-chain deadline or condition continued operations on the federal application status of every commercial partner. From their perspective, the agency has introduced additional requirements that substantially alter the protections granted to applicants during the transition.

The companies also contend that the restrictions amount to a substantive regulatory change issued without the public notice-and-comment process ordinarily required for legislative rules. Their petitions additionally characterize the DEA’s approach as arbitrary and capricious, arguing that regulators failed to adequately consider economic consequences and the reliance interests of businesses operating within existing state markets. A central legal question is whether the October document merely explains restrictions already established by federal law or imposes new obligations that required additional regulatory procedures. The DEA’s guidance expressly states that it does not independently carry the force of law, a distinction that could become important when the court evaluates the challenges.

DEA Guidance Includes Limited Inventory and Laboratory Exceptions

Although the restrictions could significantly alter commercial relationships, the DEA has included certain exceptions intended to reduce disruption. Timely dispenser applicants and distributor applicants may continue possessing, dispensing, and distributing qualifying medical marijuana inventory obtained before the October 30 guidance was issued, including products originally purchased from businesses lacking qualifying federal status. This provision allows some previously acquired inventory to remain in circulation rather than requiring immediate disposal or removal from the regulated marketplace. However, the language does not expressly provide manufacturers with the same inventory allowance, potentially creating different consequences for growers, processors, distributors, and dispensaries.

The DEA also recognizes that medical cannabis testing laboratories may not yet have received appropriate federal registrations. Under limited circumstances, the agency says it does not intend to penalize qualifying operators for sending small quantities of medical cannabis to unregistered, state-licensed laboratories for required testing. This discretion applies only under specified conditions involving state law, laboratory availability, and detailed recordkeeping. The federal government maintains that Schedule III medical marijuana must operate within a controlled distribution system designed to prevent unauthorized transfers and maintain accountability. The dispute therefore involves balancing those federal oversight objectives against the potential commercial disruption caused by imposing them on established state-regulated markets.

Medical Marijuana Patients Could Face Product Shortages and Reduced Access

Although the lawsuits primarily concern commercial registration requirements, the potential consequences extend beyond cannabis businesses. Medical marijuana patients often depend on consistent access to specific products, cannabinoid formulations, and delivery methods. Patients managing chronic pain, neurological conditions, severe nausea, or other qualifying medical conditions may have developed preferences for products that they believe provide reliable symptom relief. If dispensaries can no longer purchase from familiar cultivators and manufacturers, certain products could become temporarily unavailable, even when alternative cannabis suppliers remain active within the same state.

Supply interruptions could also affect pricing, product selection, and geographic availability. Smaller medical cannabis markets may have fewer federally qualified processors or manufacturers capable of replacing existing suppliers. Vertically integrated businesses facing restrictions on internal product transfers could experience particularly difficult inventory challenges. However, the scale of any patient disruption remains uncertain, and the November 29 guidance does not automatically require every dispensary to close or prohibit all existing medical cannabis inventory from being sold. The severity of the impact will depend on individual companies’ registration status, available inventories, alternative suppliers, and any relief granted by the courts.

Federal Cannabis Oversight Raises Questions for State Marijuana Programs

The broader dispute highlights continuing tensions between federal marijuana policy and the regulatory systems developed independently by individual states. State medical marijuana programs generally establish their own requirements for cultivation, processing, testing, transportation, and retail distribution. Companies operating under these systems may have invested substantial resources in specialized facilities, transportation arrangements, and long-term purchasing agreements. Introducing an additional federal registration requirement can create overlapping obligations, particularly when businesses already comply with extensive state licensing and product-tracking rules.

The challenge becomes more complicated in states permitting both medical and recreational marijuana. Federal officials have raised concerns about businesses operating under combined licensing structures, where medical and adult-use cannabis activities may occur within the same commercial organization. The DEA has issued notices proposing registration denials in several jurisdictions, citing concerns involving federal controlled-substance requirements and the separation of medical and recreational markets. These decisions have increased uncertainty about whether certain state-licensed operators will ultimately qualify for federal registration. The November lawsuits therefore arrive during a larger debate over how the federal government should integrate established state cannabis programs without undermining the infrastructure those programs depend upon.

Schedule III Reform Offers Benefits but Also Creates Complications

Moving qualifying medical marijuana activities into Schedule III carries potentially significant benefits for businesses operating within the new federal framework. One important consideration involves Section 280E of the Internal Revenue Code, which prevents businesses trafficking in Schedule I or Schedule II controlled substances from claiming ordinary federal business deductions. Qualifying medical marijuana activities classified under Schedule III may therefore receive more favorable federal tax treatment, although implementation questions and the allocation of expenses between medical and recreational operations remain subject to further guidance. Federal registration may also improve regulatory clarity for certain medical cannabis activities, provided companies satisfy applicable requirements.

The current litigation illustrates that these potential benefits are accompanied by substantial administrative and operational challenges. Federal registration requires businesses to navigate inspections, controlled-substance recordkeeping, inventory controls, and other requirements that may differ from state systems. Manufacturers and distributors can face particularly complicated approval procedures because of production controls, facility inspections, and federal quota considerations. Businesses that previously relied exclusively on state licensing must now evaluate how federal oversight affects purchasing agreements, product movement, and internal corporate structures. Rather than producing an immediate and uniform transition to federal legality, the Schedule III framework has created a complex regulatory environment with different consequences for different categories of cannabis businesses.

Federal Appeals Court Faces Pressure to Act Before November 29

The immediate focus of the litigation is whether the D.C. Circuit will temporarily block the disputed restrictions before the approaching compliance date. The first group of petitioners requested court action or an administrative stay before November 25, arguing that the loss of suppliers, customers, employees, and commercial relationships could cause damage that a later favorable ruling would not fully repair. The Pennsylvania companies have similarly warned that the restrictions could force operational changes before the court has an opportunity to resolve the underlying legal questions. As of November 20, no court order suspending the November 29 deadline has been confirmed.

A temporary stay could preserve existing commercial arrangements while judges consider whether the guidance is legally enforceable and consistent with the April rescheduling order. Denial of emergency relief would leave businesses confronting the DEA’s stated compliance expectations, although the lawsuits could continue on their merits. The court may also need to examine whether the agency’s document constitutes a reviewable final action, particularly given its disclaimer that the guidance is not independently binding. Whatever the immediate result, the litigation could help define the boundaries of federal oversight as cannabis companies transition into Schedule III regulation. For now, the approaching November 29 deadline has transformed medical marijuana rescheduling from a long-awaited federal policy victory into an urgent legal and commercial test for the industry.

Leave a Reply

Your email address will not be published. Required fields are marked *